Lifeline extended: sickle cell patients keep beneficial treatment

NCT ID NCT04657822

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study allows sickle cell disease patients who benefited from crizanlizumab treatment in previous Novartis trials to continue receiving the medication. It's designed for patients who have completed earlier studies but don't yet have access to commercially available treatment. The study will monitor safety while providing continued access to the therapy for up to 10 years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Augusta University Georgia
RECRUITING

Augusta, Georgia, 30912, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Childrens Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104-4399, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Childrens National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Cook Childrens Medical Center
COMPLETED

Fort Worth, Texas, 76104, United States
East Carolina University
COMPLETED

Greenville, North Carolina, 27834, United States
East Carolina University
COMPLETED

Greenville, North Carolina, 27858, United States
Novartis Investigative Site
COMPLETED

Brussels, 1000, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Laken, 1020, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Liège, 4000, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Salvador, Estado de Bahia, 41253-190, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Ribeirão Preto, São Paulo, 14051-140, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

São Paulo, São Paulo, 01232-010, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Cali, Valle del Cauca Department, 760012, Colombia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Montería, 230004, Colombia
Novartis Investigative Site
COMPLETED

Créteil, 94010, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Paris, 75015, France
Novartis Investigative Site
COMPLETED

Paris, 75015, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Padua, PD, 35128, Italy
Novartis Investigative Site
COMPLETED

Orbassano, TO, 10043, Italy
Novartis Investigative Site
RECRUITING

Beirut, 113-0236, Lebanon
Novartis Investigative Site
RECRUITING

Tripoli, 1434, Lebanon
Novartis Investigative Site
RECRUITING

Khoudh, 123, Oman
Novartis Investigative Site
COMPLETED

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Madrid, 28009, Spain
Novartis Investigative Site
WITHDRAWN

Hatay, Antakya, 31101, Turkey (Türkiye)
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Adana, Saricam, 01330, Turkey (Türkiye)
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Adana, Yuregir, 01250, Turkey (Türkiye)
University Of Alabama
RECRUITING

Birmingham, Alabama, 35233, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE